👥 MFX has developed the Cyto Engine Stack, which improves scalability by using cassettes.
🧪 Each cassette has a similar microenvironment, allowing for easy scaling up of manufacturing volumes.
📈 The cassettes can be stacked into a single instrument, allowing for independent control and monitoring of each process.
💰 MFX has secured funding from the UK’s national innovation agency to bring their product to market.
🔬 The company aims to release its first Cyto Engine product in 2025.
Introduction:
This article discusses a U.K. company called MFX (formerly MicrofluidX), which is developing scalable cell therapy manufacturing technology. The company has developed the Cyto Engine Stack, which uses cassettes to improve scalability and eliminate the need for new experiments at each volume. MFX aims to share its technology with early adopters in academia, biotech, and pharmaceutical companies.
- MFX has developed the Cyto Engine Stack, which utilizes cassettes to improve scalability in cell therapy manufacturing.
- The cassettes have a consistent microenvironment regardless of size, making it easier to scale up by using larger cassettes or stacking multiples.
- The technology allows for independent control and monitoring of each process within the stacked bioreactor cassettes.
- MFX has received funding from the U.K.’s national innovation agency, Innovate UK, to bring their product to market.
- The company aims to develop additional monitoring technologies, such as next-generation imaging and metabolite monitoring, before launching their first Cyto Engine product in 2025.
Conclusion:
MFX’s Cyto Engine Stack offers a promising solution to the scalability challenges in cell therapy manufacturing. The use of cassettes allows for easy scaling up without the need for extensive new experiments. This technology has the potential to accelerate the development and production of cell therapies, leading to improved patient access and outcomes in this emerging field.
